Chronic exposure to beta-blockers attenuates inflammation and mucin content in asthma model

Inverseon, Inc. has announced the publication of a rapid communication of groundbreaking research led by Professor Richard Bond of the University of Houston, Inverseon's Scientific Founder.

In the March article by Nguyen, et. al., in the American Journal of Respiratory Cell and Molecular Biology 2008; 38: 256-262, entitled, "Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma Model," airway mucus hypersecretion and inflammation were almost completely reversed upon treatment with certain beta blockers. The Journal commented that, "This research may result in a paradigm shift in the treatment of asthma. This research demonstrates the importance that duration of therapy has on clinical and physiologic responses."

"It is gratifying to see these findings, which were originally described in Prof. Bond's laboratory, confirmed in a respected independent laboratory," commented William J. Garner, MD, Chairman of Inverseon.